Evogene (EVGN) trades at $0.50 with a $6 million market cap, $13 million in cash, and an AI drug discovery platform. We break down the fundamentals and the Nasdaq delisting risk.
Evogene (NASDAQ: EVGN) is not a stock most investors have heard of. It does not appear on any watchlist driven by momentum or analyst upgrades. There is no Reddit thread making the bull case. No ETF rebalancing forcing it higher. It is a small Israeli computational chemistry company trading at around $0.50 a share, with a market cap of approximately $6 million, and a price chart that has moved in one direction over the past three years.
That direction is down.
But small and falling are not the same thing as worthless. Evogene has an AI-driven small-molecule discovery platform with real commercial partnerships, more than $13 million in cash on its balance sheet as of year-end 2025, a restructured cost base, and a focused strategic direction that management committed to publicly in early 2026. The question — and it is a genuinely open one — is whether any of that matters at a stock price below $1 with a Nasdaq delisting clock ticking.
What Evogene Actually Does
Evogene was founded in 1999 in Rehovot, Israel — the same technology corridor as the Weizmann Institute — on a premise that has become more credible with time: that artificial intelligence and computational biology can radically accelerate the discovery of new molecules for both pharmaceutical and agricultural applications.
Its core asset is ChemPass AI™, a generative AI platform for small-molecule design. If you want a broader view of how AI is reshaping the investment landscape, see our AI stock analysis hub. It uses machine learning, physics-based modeling, and multi-objective optimisation to design drug candidates or agricultural chemicals faster and more cheaply than traditional wet-lab discovery. The business model is licensing: pharma and agri-chemical partners pay for access and milestone rights rather than building the capability themselves.
Over its history, Evogene operated through several subsidiaries across human health, agriculture, and industrial applications. In 2025, management made a clear strategic choice: exit the subsidiaries, sell the non-core assets, and concentrate everything on ChemPass AI. Lavie Bio was sold to ICL Group. Its microbiome subsidiary Biomica is being wound down. Medical cannabis subsidiary Canonic was shut in 2024. What remains is a company focused on one platform and two markets: pharma and agriculture.
Recent News & Catalysts
The recent spike in EVGN shares was driven by a sequence of announcements that have come in rapid succession since late June 2026. Here is what has actually happened:
Is Evogene Profitable?
No. Evogene is not profitable, has never been profitable as a public company, and is not expected to reach profitability in the near term. This is the most important single fact about the stock and should be understood clearly before reading anything else.
The numbers tell the story directly. In full-year 2025, Evogene generated $3.9 million in revenue and recorded a $14.0 million operating loss. That means for every dollar of revenue the company brought in, it spent roughly three and a half dollars operating the business. The net loss for the year was $7.8 million — narrower than the operating loss because of a $6.4 million one-time gain from selling Lavie Bio assets to ICL. Remove that gain and the underlying loss is closer to $14 million.
In Q1 2026, revenue fell further to $0.3 million while the net loss came in at $5.9 million — a net margin of approximately -1,967%. Operating cash outflow for the trailing twelve months was $13.5 million.
| Metric | FY 2025 | FY 2024 | Q1 2026 |
|---|---|---|---|
| Revenue | $3.9M | $8.5M | $0.3M |
| Gross profit | -$0.2M | +$6.8M | est. negative |
| Operating loss | -$14.0M | -$18.8M | est. -$5M+ |
| Net loss | -$7.8M* | -$18.1M | -$5.9M |
| EPS (diluted) | -$1.70 TTM | negative | -$0.60 |
| Operating cash flow | -$13.5M | -$10.4M | est. -$3M+ |
| Net margin | -203% | -213% | ~-1,967% |
*2025 net loss includes $6.4M one-time gain from Lavie Bio asset sale. Underlying operational loss was closer to $14M.
The improvement in net loss from 2024 ($18.1 million) to 2025 ($7.8 million) is real but misleading at face value. It was driven almost entirely by cost cuts and the Lavie Bio asset sale, not by revenue growth or a path to profitability. Operating expenses did fall meaningfully — from $18.8 million in 2024 to $13.8 million in 2025 — and that is a genuine positive. But with revenue also falling, the gap between income and expenses has not closed in any meaningful way.
There is no analyst estimate suggesting Evogene reaches profitability before 2028 at the earliest, and that scenario requires ChemPass AI landing significant commercial licensing deals that are not yet visible in the pipeline. Until that happens, Evogene is a cash-burning platform company whose financial viability depends on its balance sheet runway, not its income statement.
The Financials
Revenue
Full-year 2025 revenues came in at approximately $3.9 million, down from $5.6 million in 2024 and from the peak years when Lavie Bio and AgPlenus generated licensing payments from Corteva and Bayer. Q1 2026 revenue fell further to approximately $0.3 million, compared to $2.3 million in Q1 2025 — a 87% year-over-year decline driven by the completion of those deals and the Bayer collaboration ending in April.
The revenue pattern matters to understand: much of 2023–2024 revenue came from one-time licensing events, not recurring contracts. The company’s Casterra seed business provides the most organic revenue line, but it is small and agricultural-cycle dependent. Without a new significant licensing deal, the revenue baseline for 2026 is around $1–2 million for the full year.
| Period | Revenue | Net Loss | Op. Loss | Cash |
|---|---|---|---|---|
| FY 2023 | $5.6M | -$25.9M | -$26.5M | $31.1M |
| FY 2024 | $8.5M | -$18.1M | -$18.8M | $15.3M |
| FY 2025 | $3.9M | -$7.8M | -$14.0M | $13.0M |
| Q1 2026 | $0.3M | -$5.9M | est. -$5M+ | est. ~$10M |
Earnings Per Share
Evogene is not profitable and is not expected to be in the near term. TTM diluted EPS sits at -$1.70. Q1 2026 EPS was -$0.60, missing analyst estimates of -$0.27 by more than double — a significant miss that reflects how rapidly the revenue base has contracted since the Bayer and Corteva deals concluded. The net loss improvement in 2025 ($7.8 million vs $18.1 million in 2024) is partly explained by the $6.4 million gain from the Lavie Bio asset sale — a one-time item. Strip that out and the underlying operational picture is harder: a $14 million operating loss against $3.9 million in revenue.
Balance Sheet
This is where the Evogene story becomes more nuanced. As of December 31, 2025, the company held approximately $13.0 million in cash and short-term deposits. There is no meaningful long-term debt. The current ratio sits at 4.54 — Evogene has significantly more current assets than current liabilities, and this is not a company facing immediate insolvency.
The concern is burn rate. Cash usage in 2025 was approximately $13.5 million operating. At a similar run rate, the company has roughly four to five quarters of runway from year-end 2025 — call it late 2026 to early 2027. Two factors partially offset this: Lavie Bio and Biomica are expected to distribute approximately $4.25 million combined to Evogene during 2026 via court-approved dividends, and the cost reduction programme implemented in 2025 (operating expenses fell from $18.8 million in 2024 to $13.8 million in 2025) should reduce the burn in 2026.
The Nasdaq Delisting Risk
This cannot be treated as a footnote. Evogene received a formal Nasdaq notice for noncompliance with the minimum bid price rule after its stock remained below $1.00 for 30 consecutive business days. The cure deadline is September 28, 2026. The stock must trade at or above $1.00 for at least 10 consecutive business days before that date to regain compliance, per Nasdaq Listing Rule 5810(c)(3)(A).
As of mid-July 2026, the stock is at approximately $0.50–$0.75. To sustain $1.00+ for 10 consecutive days before September 28 requires either sustained positive news flow — specifically the kind of commercial deal that changes market sentiment — or a reverse stock split. A reverse split mechanically raises the price but does not change underlying value and tends to be received poorly by the market.
If the company fails to meet the deadline and does not qualify for a second cure period, Nasdaq delisting would force many institutional holders to sell regardless of their view on the company’s prospects. That selling pressure could push the stock significantly lower from current levels.
The Bull & Bear Case
- ChemPass AI has real institutional validation — Tel Aviv University, Google Cloud, QUT, LMU Munich
- $13M cash, no debt, current ratio 4.54 — not an imminent bankruptcy story
- Operating expenses down from $18.8M (2024) to $13.8M (2025) and still falling
- Biomica Phase 1 met safety endpoint — positive clinical signal from pipeline
- $6M market cap means one meaningful pharma licensing deal could re-rate the stock significantly
- Both listed on Nasdaq and TASE — benefits from Israeli tech investor base
- Q1 2026 revenue $0.3M — 87% YoY decline; no near-term revenue visibility
- EPS missed estimates by 122% in Q1 2026 — worse than market expected
- Nasdaq delisting deadline September 28, 2026 — real forced-selling risk
- Bayer collaboration ended April 2026 — removed a recurring revenue source
- Academic partnerships (TAU, QUT) have no disclosed financial terms — credibility signals, not revenue
- Competing against Schrodinger, Recursion Pharma, and well-funded startups in AI drug discovery
- Warrant structure creates future dilution at $1.25 if stock recovers
Is This a Buy Opportunity?
The honest answer is: for most investors, no — and the reason is not that the platform lacks merit. The reason is the risk profile.
At $0.50–$0.75 per share with a $6 million market cap, Evogene is priced like a company that might not exist in 18 months. That is not irrational pricing. The cash runway is finite, revenue is shrinking, the Nasdaq clock is ticking, and there is no near-term path to profitability. A lot has to go right.
What the stock is not is a value buy in the way a Pfizer or beaten-down blue chip might be. This is not a case where you have predictable cash flows, a dividend, and a question of whether the market is too pessimistic about a recognisable business — the kind of story we explored in our Pfizer fundamental analysis. This is a pre-commercial AI platform with declining revenue, burning cash, and binary outcomes. The fundamental case requires believing ChemPass AI lands a significant pharma licensing deal — something the market is currently refusing to price in.
For a risk-tolerant investor who understands the binary nature of this kind of bet, there is a speculative argument: at $6 million market cap, even one meaningful pharma partnership could create substantial upside. The downside is, in the worst case, complete loss. That asymmetry is the core of the bull case — and also why position sizing matters more than almost anything else if you decide to participate.
Evogene is not a stock you buy on fundamentals. It is a bet on whether ChemPass AI gets commercial traction before the cash runway runs out. The recent partnerships — Tel Aviv University, QUT, Google Cloud — suggest the platform is earning real institutional respect within the academic and technology ecosystems. None of that has translated into the kind of pharma licensing revenue that would justify a re-rating.
Watch for two things. First, whether a named commercial pharma partner signs a licensing deal with disclosed economics — that is the event that changes the thesis from speculative to supported. Second, whether the stock can reach and hold $1.00 before September 28, 2026. If it cannot, the delisting risk alone creates a technical selling event that has nothing to do with the company’s actual prospects.
If you already own EVGN, the Tel Aviv University announcement is a positive development. If you are considering it for the first time, size the position accordingly: this is a high-risk, binary-outcome micro-cap, not a misunderstood value stock waiting to be discovered.
What to Watch Next
Three catalysts define the EVGN story in the near term. First, whether the Nasdaq compliance deadline triggers a reverse split decision or is resolved by the stock naturally recovering to $1.00+ — management will need to communicate their approach before September 28. Second, Q2 2026 earnings on August 20, 2026 — the revenue number will either confirm or deny whether the business has stabilised at a new lower baseline. Third, and most importantly, any announcement of a named commercial pharma partner licensing ChemPass AI with disclosed financial terms — that is the single most important event for the investment thesis.
This article is for informational purposes only and does not constitute financial or investment advice. Evogene (EVGN) is a micro-cap stock with high volatility and significant risk of loss. All investments involve risk. Data sourced from Evogene SEC filings, press releases, StockTitan, Robinhood, Public.com, and Investing.com. Accurate as of July 14, 2026. Always conduct your own research before making investment decisions.